46
The Agilent Technologies SureSelect™ Platform for Target Enrichment Focus your next-gen sequencing on DNA that matters Emily M. Leproust, Ph.D. Director Applications and Chemistry R&D Genomics

The Agilent Technologies SureSelect™ Platform for … · Distinct Project Needs SureSelect Target Enrichment System SureSelect DNA Capture Array ... Applications to Mendelian disorders

  • Upload
    trinhtu

  • View
    219

  • Download
    0

Embed Size (px)

Citation preview

The Agilent Technologies

SureSelect™ Platform for Target Enrichment

Focus your next-gen sequencing on DNA that matters

Emily M. Leproust, Ph.D.

Director Applications and Chemistry R&D – Genomics

Agenda:

• Introduction

• Applications for Mendelian diseases research

• Custom biomarker discovery and profiling

• Applications for cancer biomarker discovery and profiling

• Automation

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 2

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 3

Target Enrichment: A Highly Enabling Process

What?

• Also referred to as genome partitioning, targeted re-sequencing, DNA capture…

• Captures genomic material of interest for next generation sequencer (i.e. Illumina, SOLiD, 454 etc…)

Why?

• Sequence your regions of interest!

• Enables focus on a subset of the genome

• Saves both time and money for downstream sequencing

• Identify homozygous and heterozygous variants

in targets relative to the reference genome

gDNA

Enriched library

Sequencing Technology Keeping up with Science

(from http://www.sciencemag.org/cgi/content/full/291/5507/1221/F1)

Older Methods

Appropriate

Lower Throughput

Discovery

PCR + Sanger

Sequencing

Newer Methods

Appropriate

High Throughput

Discovery

SureSelect™

Platform +

Next-gen

Sequencing

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 5

Agilent’s SureSelect™ Platform: New Options

SureSelect Target

Enrichment System*Developed in collaboration

with the Broad Institute

Dr. Chad Nusbaum et al.

SureSelect

DNA Capture ArrayDeveloped in collaboration

with Cold Spring Harbor

Dr. Greg Hannon et al.

*Flagship Method

Agilent 60mer Array

1-3 µg gDNA

1-5 µg gDNA

(with WGA)

20 µg gDNA

(unamplified)

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 6

Distinct Target Enrichment Products for

Distinct Project Needs

SureSelect Target

Enrichment

System

SureSelect DNA

Capture Array

Throughput High Low

Study Sizes 10-1,000s samples 1-10 samples

DNA Input 1-3 µg* 1-20 µg**

Capture of

Target DNA

Up to 6.8 Mb (1x tiling, 120mer

baits) for custom; catalog products

1Mb (20x tiling)

(Custom 60-mer

baits)*minimum of 500 ng of prepped sample required

**Depends upon use of whole genome amplification.

or

0.5µg

<3µg

Library Preparation• Illumina• SOLiD

Hybridization / Capture24 hours

Baits:

- cRNA probes

- Long (120bp)

- Biotin labeled

- User-defined (eArray)

- SurePrint synthesis

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 7

Bead Separation

Wash / Elution / Amp

Advantages of Agilent Target Enrichment:

• Long baits tolerate mismatches

• RNA-DNA hybrids stronger than DNA-DNA

• RNA probe is strand-specific:

Allows large molar excess of bait,

Target-limited; improves uniformity

• Easily automated: All steps liquid handling

• Low input DNA (< 3 ug)

• 24hrs hybridization

• Same high quality Nucleic Acids as Agilent arrays

• Working on Solution Enrichment since 2006, license from Broad

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 8

SureSelect™ Target Enrichment System: Workflow

24 hours

0.5µg

<3µg

SOLiD 3

SOLiD 4

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 9

SureSelect™ Target Enrichment System: Workflow

Illumina GAIIx

HiSeq 2000

24 hours

0.5µg

<3µg

Page 10

Broad Paper on Cover of February, 2009 Nature Biotechnology Underlying Technology of SureSelect™ Target Enrichment System

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Agilent SureSelect™ Target Enrichment Efficacy:

Sample Coverage Plot

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 11

This plot (generated in the UCSC Genome Browser) shows sequence coverage data for a representative portion of the Agilent SureSelect Target Enrichment demo kit, which covers the RefSeq exons on the non-pseudoautosomal portion of Chromosome X using 2x tiling. In red is the log of the sequence coverage. Bait coordinates are denoted in black and the exons that constitute the target region are in blue. Sequence coverage is higher for those exons that are covered by more than one overlapping bait

269

0

SureSelect Bait Coordinates: Black Bars

2x tiling design approach

Agenda:

• Introduction

• Applications for Mendelian diseases research

• Custom biomarker discovery and profiling

• Applications for cancer biomarker discovery and profiling

• Automation

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 12

Exon capture is powerful to study Mendelian diseases

• Mendelian diseases are caused by coding mutations (with some exceptions)

• Exons are only ~1-1.4 % of human genome (30-50Mb)

• Primarily protein coding regions

Advantages:

• Much less sequencing

• ~5% of WGS, so up to 20x more samples

Disadvantage:

• Miss non-coding variants

Why coding+?

• More interpretable

• Easier to follow up

• Especially adapted to study of Mendelian diseases

• CCDS exons – v1

• CCDS + RefSeq – 38Mb v2 (Broad)

• GENCODE – 50Mb (Sanger)

• Includes ncRNA

• All Exons on X chromosomes

• 7674 exons

• 3Mb

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 13

Applications to Mendelian disorders

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 14

… and many more to come

• The Problem: Linkage analysis confirmed family inheritance pattern to a 28 Mb region (build 36)

• >200 genes contained in 28 Mb region; daunting task to sequence and validate all the variants.

• Solution: Identify a 2nd family that manifests the syndrome, determine linkage and perform targeted sequencing using the X-demo kit on heterozygote females of both families

Page 15

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

• Target : 2.7 Mb; 36 bp SE seq on Illumina GA

• Findings

• Family 1 heterozygote showed a frameshift due to an A insertion in RBM 10 (RNA binding motif 10)

• Family 2 heterozygote showed a G to A substitution in RBM 10 (RNA binding motif 10)

• Both mutations were confirmed by Sanger Sequencing

• Inhibition of the orthologous Rbm 10 expression in developing mouse embryo using anti-sense probes showed patterns that were consistent with observed human malformations

Page 16

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Page 17

Human All Exon Kits – Most comprehensive coverage

Original design Exome V2 50Mb design

CCDS Sept. 2008

CCDS Sept. 2008 + additional RefSeq

content including CCDS Sept. 2009 exons

GENCODE and Sanger (includes CCDS and

Broad defined v2 content as well)

CCDS (Sept. 2009) 93.76% 99.01% 99.86%

CNV (Mar. 2010) 23.98% 27.49% 30.62%

Ensembl (6/16/2010) 65.58% 71.37% 75.24%

miRNA (miRBase 14) 90.00% 90.00% 92.78%

GenBank (6/16/2010) 75.96% 89.07% 90.74%

RefSeq Genes (6/16/2010) 86.69% 93.29% 96.47%

RefSeq Transcripts (6/16/2010) 88.85% 95.07% 97.50%

Total 37Mb 38Mb 50Mb

Developped with Broad Broad Sanger

• Human All Exon kits can be customized (PLUS) with up to 6.8Mb additional custom content • Human All Exon kits can be multiplexed on SOLiD4 and HiSeq2000

New

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Human All Exon 50Mb – 2x76bp, 50-60M HQ reads

Page 18

76.3%

85.1%

96.7%87.9%

77.5%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

% on target +/-

100bp

Uniformity (3/4 mean with upper

tail):

% bases with 1x

coverage

% bases with 10x coverage

% bases with 20x coverage

Most comprehensive Human All Exon content available

38Mb design = a subset of 50Mb

Sequencing capacity: • 0.5-1 sample / lane GAIIx• 1-3 samples / lane HiSeq• 5-10 samples /flowcell SOLiD4

Chemistry recommended:• PE 2x76bp Illumina• PE 50+25 SOLiD

Multiplexing:• Illumina• SOLiD

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Comparison of SNP calls with HapMap

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 19

99.1% 99.2%98.4% 98.0%

95.7%94.9%

70%

75%

80%

85%

90%

95%

100%

Human All Exon v2 Human All Exon 50Mb

GT is REF GT is variant HOM

GT is variant HET

99.8% 99.7%98.2% 98.1%98.5% 98.3%

99.4% 99.3%

70%

75%

80%

85%

90%

95%

100%

Human All Exon v2 Human All Exon 50Mb

GT is REF GT is variant HOM

GT is variant HET OVERALL

Genotype Concordance vs. HapMapGenotype Sensitivity vs. HapMap

All Exon Plus (Add custom content to your All Exon)

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 20

All Exon Library

+

Your Custom Library

Enter Your Custom Regions in eArray

CCDS exons>1000 ncRNAs

38Mb

Your regions of interest

Is the Human All Exon not hitting all of your regions of interest?

Human All Exon Plus (All Exon + custom content)

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 21

1 tube capture, 1 lane seq. at 2x76bp on GAIIx = ~2Gb

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Exome +

0.87 Mb

Exome +

1.7 Mb

Exome +

3.4 Mb

Exome +

6.8 Mb

Exome

Control

SNP Analysis vs. HapMap

Sensitivity Concordance

0

5000

10000

15000

20000

25000

30000

35000

Exome +

0.87 Mb

Exome +

1.7 Mb

Exome +

3.4 Mb

Exome +

6.8 Mb

Exome

Control

22394

23224

24337

26352

21976

4480

5528

5816 6

182

5173

No. S

NP

s

SNP Analysis vs. dbSNP

Concordant Novel Mismatched

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 22

Efficient Capture of 5bp deletion on the

X-Chromosome: Menke’s Syndrome

hg18_ChrX_77131408_77131467_+ : Wildtype Bait Design

CTATTGTTTATCAACCTCATCTTATCTCAGTAGAGGAAATGAAAAAGCAGATTGAAGCT

CTATTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAA

ATTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAG

TTGTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGC

GTTTATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAG

TATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATT

ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG

ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG

ATCAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTG

CAACCTCATCTT-----AGTAGAGGAAATGAAAAAGCAGATTGAA

CCTCATCTT-----A-TAGAGGAAATGAAAAAGCAGATTGAAGCT

SureSelect™ Target Enrichment Kit Efficiently Captures 5 bp Mutant

Readout on Illumina GA

Agenda:

• Introduction

• Applications for Mendelian diseases research

• Custom biomarker discovery and profiling

• Applications for cancer biomarker discovery and profiling

• Automation

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 23

Other Applications of Targeted Re-Sequencing

• Capture any custom genomic regions (introns, exons, UTRs, regulatory, etc.)

• Ideal for biomarkers discovery and profiling (e.g. cancer)

• Ideal for custom SNP follow-up

• Ideal for characterization of large sample cohorts

Key enabling features:

• High throughput

• 12 Illumina indexes / up to 96 samples per run

• 16 SOLiD barcodes / up to 128 samples per run

• Only pay what you capture, scalable from 0.2 to 6.8Mb (sweet spot for 3rd Gen Seq)

• <0.2 Mb

• 0.2 – 0.5Mb

• 0.5 – 1.5Mb

• 1.5 – 3Mb

• 3 – 6Mb

• Very reproducible, excellent allelic balance for accurate heterozygote calls

• Custom and catalog content (kinome)

• Automation (library prep and capture)

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 24

• Inherited loss-of-function mutations in the tumor suppressor genes BRCA1, BRCA2, and

multiple other genes predispose to high risks of breast and/or ovarian cancer. Cancer-

associated inherited mutations in these genes are collectively quite common, but individually

rare or even private.

• To determine whether massively parallel, “next-generation” sequencing would enable

accurate, thorough, and cost-effective identification of inherited mutations for breast and

ovarian cancer, we developed a genomic assay to capture [with Agilent’s custom SureSelect],

sequence, and detect all mutations in 21 genes, including BRCA1 and BRCA2, with inherited

mutations that predispose to breast of ovarian cancer.

• There were zero false-positive calls of nonsense mutations, frameshift mutations, or

genomic rearrangements for any gene in any test sample.

• This approach enables widespread genetic testing and personalized risk assessment for

breast and ovarian cancer.

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 25

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 26

Excellent allelic balance

Deletion up to 19bp

eArray: a free tool to design custom SureSelect libraries

Customer A

Genomic locations #1Design parameters

Genomic locations #2Design parameters

Genomic locations #3Design parameters

Baits #1

Baits #2

Baits #3

Virtual bait library

Bait design

Bait design

Bait design

Librarydesign

Kit size

Quote

eArray Webportal

Customer B

Real DNA bait library

RNA bait library

Kit

Send to ManufacturingPass on Kit size info, etc.

Assemble kit

Ship Kit to Customer

Order library

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 27

Up to 55,000 Unique Baits/Kit

eArray – Supported species

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 28

H. sapiens, M. musculus, R. norvegicus, D. melanogaster, C. elegans, C. familiaris, S. cerviseae, S. pombe, G.

gallus, B. taurus, A. thaliana

eArrayXD – Import your own genomes

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 29

Available now

Indexing/Barcoding Procedure with SureSelect

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 30

Similar protocol available for SOLiD (x16 primers)

Illumina / SOLiD primer

SureSelect Pre-Capture

Primer

Prepared Library without Index Tag

2. Pre-Capture PCR

4. Post-Capture PCR

SureSelect Universal Primer

Illumina / SOLiD

Index Primer (Up to 12/16)

3. SureSelectHybridization/Capture

IndexCaptured

Library with Index Tag

1. Library prep • For optimum performance:

• Capture

• Index

• Pool

• Sequence

• Combine multiple samples per

sequencing lane

• Save on capture costs with

production scale

• Pay only for the Mb you capture:

• <0.2Mb 12-16 samples

• 0.2 – 0.5Mb

• 0.5 – 1.5Mb

• 1.5 – 3Mb 3-4 samples

• 3 – 6.8Mb

0.900.79

1.17

1.05

1.05

1.15

0.96

1.021.05

0.93

0.90

1.20

0.86

0.98

1.03

0.96

Standard Index Representation in Single SOLiD Quad

BC1

BC2

BC3

BC4

BC5

BC6

BC7

BC8

BC9

BC10

BC11Fold Representation Relative to the Mean

SOLiD Barcoding –16 barcodes of 0.2Mb Capture in 1 SOLiD Quad, 1x50bp, 30M reads

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 31

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Percentage reads in targeted regions:

Percentage reads in regions +/-100bp:

Percentage reads in regions +/-200bp:

HQ Reads

Mean/Barcode 1,844,819

Median/Barcode 1,843,950

Total/Quad 29,517,104

SOLiD Barcoding – Comparison with dbSNP16 barcodes of 0.2Mb Capture in 1 SOLiD Quad, 1x50bp, 50M reads

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 32

• Comparison of observed SNP calls vs. dbSNP 130

• We see 100% concordance rate with dbSNP across all called SNPs.

• There are, on average, ~80 novel SNPs called for each sample.

http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit

199 201 205 203 206 206 202 201 202 204 199 204 199 200 200 199

0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0

85 8797 97 91

108101 96 99

108

7999

96 10287 92

0

50

100

150

200

250

300

350

BC1 BC2 BC3 BC4 BC5 BC6 BC7 BC8 BC9 BC10 BC11 BC12 BC13 BC14 BC15 BC16

Nu

mb

er

of

SNP

sit

es

Barcode

dbSNP concordance across multiple barcodes

Novel Sites

dbSNP Mismatches

dbSNP Concordant

Agenda:

• Introduction

• Applications for Mendelian diseases research

• Custom biomarker discovery and profiling

• Applications for cancer biomarker discovery and profiling

• Automation

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 33

Cost: € 40,000 per patient/year

Targeted Therapies: Expensive, Can they be more effective?

100 %

0 %

Survival

Time (months)

Tito Fojo and Christine Grady, J Natl Cancer Inst. 2009;10:1044-8

Slide courtesy of Rene BernardsAgilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Herceptin

KRAS mutation alters response to EGFR therapy

in Colon Cancer

Mutant KRAS+EGFR-EGFR

Wild type KRAS+EGFR-EGFR

Amado et al. J Clin Oncol; 26:1626-1634 2008

KRAS mut: 32% PIK3CA mut: 13%

BRAF mut: 10%

Slide courtesy of Rene BernardsAgilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Current clinically useful correlations between kinome

alterations and drug responses

• HER2 expression (breast) Herceptin

• BCR-ABL translocation (CML) Gleevec

• KRAS mutation (colon) (no response) Cetuximab

• EGFR mutation (lung) Erlotinib

Somewhat further away, but promising:

• BRAF mutation (melanoma) PLX4032

• ALK mutation/translocation (lung, neuroblastoma) PF02341066

• PIK3CA mutation (breast) (no response) Herceptin

Slide courtesy of Rene BernardsAgilent SureSelect™ Platform

Enabling Products for the Next-Generation Sequencing Workflow

SureSelect “kinome” – Discovery and profiling of

biomarkers related to disease and/or drug response

• 518 putative kinases

• 12 PI3K domain-containing genes

• 6 PI3K regulatory components

• 13 diglyceride kinases

• 18 genes frequently mutated in human cancer

• 19 genes specifically known to be mutated in breast cancer

G. Manning et al Science 298 1912 (2002)

Slide courtesy of Rene BernardsAgilent SureSelect™ Platform

Enabling Products for the Next-Generation Sequencing Workflow

Kinome Kit Performance –3-5 samples per GAIIx lane / SOLID quad

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 38

Agenda:

• Introduction

• Applications for Mendelian diseases research

• Custom biomarker discovery and profiling

• Applications for cancer biomarker discovery and profiling

• Automation

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 39

Illumina Library Prep and SureSelect Enrichment on

the Bravo Automated Liquid Handling Platform

Page 40

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing Workflow

Next-Gen Sequencing and SureSelect Overview

Shear

Genomic DNA

Repair Ends

3’-dA Addition

Adapter

Ligation

PCR

Enrichment

Prepped

Library

SureSelect

Oligo Capture

LibraryLibrary

Hybridization

Magnetic

Bead Capture

PCR

QA

Illumina

Cluster &

Sequence

Library Prep

SureSelect

Target Enrichment

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 41

Next-Gen Sequencing and SureSelect Overview

Shear

Genomic DNA

Repair Ends

3’-dA Addition

Adapter

Ligation

PCR

Enrichment

Prepped

Library

SureSelect

Oligo Capture

LibraryLibrary

Hybridization

Magnetic

Bead Capture

PCR

QA

Illumina

Cluster &

Sequence

Library Prep

SureSelect

Target Enrichment

Agilent Automation

Bravo Liquid Handler

Automated

Bead Capture

Automated

Purification

Automated

Purification

Automated

Purification

Automated

Purification

Automated

Purification

Automated

Purification

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 42

Most Comprehensive, Ever Expanding SureSelect™ Menu

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 43

ProductTarget amount (catalog

number)Reactions/kit Product Definition

X-demo 3.4 Mb 5 Exons in the human X-chr

All Exon v1 38 Mb 5-10,000Catalog content from CCDS + >1000

ncRNA

All Exon Plus38 Mb + up to 6.8 Mb of

custom content5-10,000

Add custom content to All Exoncatalog content

All Exon v2 38 Mb + RefSeq 5-10,000CCDS Sept. 2009

+ additional RefSeq

All Exon 50Mb 50Mb 5-10,000GENCODE content – Most comprehensive coverage

Multiplexable

Kinome <3Mb 5-10,000 All kinases

Indexed custom content

<0.2 Mb, 0.2-0.49 Mb, 0.5-1.49 Mb, 1.5- 2.9 Mb 3 – 6.8 Mb

10 – 5,000Cost-saving custom offering –

Illumina (12 indexes) and SOLiD (16 barcodes)

Summary: Efficient Enrichment for Re-Sequencing

• Most comprehensive Human All Exon catalog products

• New 50Mb catalog content

• Multiplexable (HiSeq and SOLiD4)

• With option to add up to 6Mb custom (Exon Plus)

• Enables biomarker discovery and profiling

• New Kinome catalog content and custom content

• Indexing/Barcoding for Illumina and SOLiD

• Scalable and affordable from 0.2 – 6.8Mb

• Free web portal, eArray, enables fully custom design

• Fastest way to biological answer

• Low DNA input

• Accurate SNP calls

• Fast, reproducible and, automatable

• Available for SE and PE on Illumina and SOLiD

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 44

Agilent SureSelect™ Platform

Enabling Products for the Next-Generation

Sequencing WorkflowPage 45

Acknowledgements

• Collaborators:

o Broad Institute

• Chad Nussbaum et. al

• Stacey Gabriel et. al

• Sheila Fisher et. al

o Sanger Institute

• Daniel Turner et.al.,

o NKI

• Rene Bernards

• Ian Majewski

o All our early access collaborators (over 20

institutions worldwide)

•Life Technologies and Illumina R&D/Marketing

QUESTIONS?Thank you